Table 4. Comparison of clinical factors between GBM patients with different statuses of 2-year survival.
| 2-year survival | P value | ||
|---|---|---|---|
| < 2 year (n = 25) | > 2 year (n = 5) | ||
| age (yr) | 59.19 | 59.15 | 0.697 |
| Sex | |||
| Female | 11 | 3 | 0.642 |
| Male | 14 | 2 | |
| Tumor volume (median) (cm3) | 36.71 | 15.92 | 0.075 |
| Surgical Intervention | |||
| Biopsy | 9 | 0 | 0.061 |
| Subtotal or partial resection | 7 | 0 | |
| Total resection | 9 | 5 | |
| Initial Treatment | |||
| CCRT | 20 | 5 | 0.566 |
| Chemotherapy or radiation alone | 5 | 0 | |
| Follow-up Treatment | |||
| Adjuvant Temozolomide | |||
| yes | 18 | 5 | 0.304 |
| no | 7 | 0 | |
| Bevacizumab | |||
| yes | 12 | 3 | 1.000 |
| no | 13 | 2 | |
| other chemotherapy agents | |||
| yes | 11 | 2 | 1.000 |
| no | 14 | 3 | |
| Radiation | |||
| yes | 4 | 0 | 1.000 |
| no | 21 | 5 | |
Note: Values are number of patients unless otherwise indicated. P values were calculated by using non-parametric Wilcoxon rank sum test on continuous data and Fisher exact test on categorical data. GBM, glioblastoma multiforme; CCRT, concurrent chemoradiation therapy with temozolomide.